+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
Sale

Global Therapeutic Drug Monitoring Market by Product (Consumables, Data Management Services, Equipment), Technology (Chromatography-MS, Immunoassays, Proteomic Technologies), Drug Class, End-User - Forecast 2024-2030

  • PDF Icon

    Report

  • 186 Pages
  • May 2024
  • Region: Global
  • 360iResearch™
  • ID: 5367869
UP TO OFF until Dec 31st 2024
1h Free Analyst Time
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.

The Therapeutic Drug Monitoring Market size was estimated at USD 3.79 billion in 2023, USD 4.38 billion in 2024, and is expected to grow at a CAGR of 16.11% to reach USD 10.78 billion by 2030 .

Therapeutic drug monitoring is the clinical testing process of measuring plasma, serum, or blood drug concentrations. These therapeutic drug monitoring processes enable designing the patient-specific dosage regimen, optimizing the effectiveness of drugs, and maintaining a certain level of drug substance in patients’ bodies. The increase in chronic disease incidences and growth in the healthcare and pharmaceutical industries create the need for therapeutic drug monitoring to monitor drug dosage safety and efficacy effectively. However, the limited availability of skilled laboratory technicians and inadequate reimbursement policies is hampering the growth of the market. Furthermore, the developments in immunoassay and other therapeutic drug monitoring technologies are creating opportunities for market growth.

Regional Insights

The therapeutic drug monitoring market shows a highly evolving landscape in the Americas owing to the increasing demand for organ transplantation, usage of precision medicines, and applications of TDM in healthcare areas, including hospital labs and private labs. The rising prevalence of chronic diseases, and increasing consumer switch towards personalized medications, tremendously increase the demand for therapeutic drug monitoring for drug development process in APAC and EMEA regions. European governments have shifted their focus towards launching the Framework Programme for Research and Technological Development, which aims to develop new personalized medicine leading to a rise in investment and funding. Governments worldwide are focusing on accelerating genomic research activities for the development of different types of drugs, and recognizing the clinical benefits of therapeutic drug monitoring is expected to raise demand for TDM from hospitals worldwide for better treatment outcomes with minimum side effects from the medication.

Product: Rising demand for data management services for efficient drug management

Consumables include indispensable disposable items such as reagents, kits, and calibrators, crucial for the accuracy of drug-level tests, and witness a growing demand due to their repetitive use. Data management services are pivotal, offering advanced solutions for efficiently handling the extensive data yielded from TDM processes, including software and systems designed for data collection, analysis, and reporting, ensuring streamlined management of crucial patient and treatment information. The equipment segment encompasses various analyzers and detectors, such as chromatography & MS Detectors for specific and sensitive drug detection, clinical chemistry analyzers for broad biochemical testing, and immunoassay analyzers for quick and effective drug quantification.

End-User: Increasing demand from hospitals where accurate drug management is essential

Hospital labs are instrumental in refining patient care, particularly for treatments requiring precise dosing due to the narrow therapeutic index, high toxicity, or individual variations in drug metabolism and action. This approach is essential in acute care scenarios and specialties such as oncology and transplant medicine, where accurate drug management is crucial to patient survival and recovery. Private laboratories cater to a broader outpatient population, collaborating closely with primary care and specialty physicians to manage long-term conditions, including mental health, cardiovascular, and autoimmune diseases. Private laboratories provide timely drug-level assessments and are indispensable in guiding physicians toward making educated decisions on dosage modifications and medication selection, thereby ensuring tailored and efficacious patient treatment plans.

Market Dynamics

The market dynamics represent an ever-changing landscape of the Therapeutic Drug Monitoring Market by providing actionable insights into factors, including supply and demand levels. Accounting for these factors helps design strategies, make investments, and formulate developments to capitalize on future opportunities. In addition, these factors assist in avoiding potential pitfalls related to political, geographical, technical, social, and economic conditions, highlighting consumer behaviors and influencing manufacturing costs and purchasing decisions.

Market Disruption Analysis

The market disruption analysis delves into the core elements associated with market-influencing changes, including breakthrough technological advancements that introduce novel features, integration capabilities, regulatory shifts that could drive or restrain market growth, and the emergence of innovative market players challenging traditional paradigms. This analysis facilitates a competitive advantage by preparing players in the Therapeutic Drug Monitoring Market to pre-emptively adapt to these market-influencing changes, enhances risk management by early identification of threats, informs calculated investment decisions, and drives innovation toward areas with the highest demand in the Therapeutic Drug Monitoring Market.

Porter’s Five Forces Analysis

The porter's five forces analysis offers a simple and powerful tool for understanding, identifying, and analyzing the position, situation, and power of the businesses in the Therapeutic Drug Monitoring Market. This model is helpful for companies to understand the strength of their current competitive position and the position they are considering repositioning into. With a clear understanding of where power lies, businesses can take advantage of a situation of strength, improve weaknesses, and avoid taking wrong steps. The tool identifies whether new products, services, or companies have the potential to be profitable. In addition, it can be very informative when used to understand the balance of power in exceptional use cases.

Value Chain & Critical Path Analysis

The value chain of the Therapeutic Drug Monitoring Market encompasses all intermediate value addition activities, including raw materials used, product inception, and final delivery, aiding in identifying competitive advantages and improvement areas. Critical path analysis of the <> market identifies task sequences crucial for timely project completion, aiding resource allocation and bottleneck identification. Value chain and critical path analysis methods optimize efficiency, improve quality, enhance competitiveness, and increase profitability. Value chain analysis targets production inefficiencies, and critical path analysis ensures project timeliness. These analyses facilitate businesses in making informed decisions, responding to market demands swiftly, and achieving sustainable growth by optimizing operations and maximizing resource utilization.

Pricing Analysis

The pricing analysis comprehensively evaluates how a product or service is priced within the Therapeutic Drug Monitoring Market. This evaluation encompasses various factors that impact the price of a product, including production costs, competition, demand, customer value perception, and changing margins. An essential aspect of this analysis is understanding price elasticity, which measures how sensitive the market for a product is to its price change. It provides insight into competitive pricing strategies, enabling businesses to position their products advantageously in the Therapeutic Drug Monitoring Market.

Technology Analysis

The technology analysis involves evaluating the current and emerging technologies relevant to a specific industry or market. This analysis includes breakthrough trends across the value chain that directly define the future course of long-term profitability and overall advancement in the Therapeutic Drug Monitoring Market.

Patent Analysis

The patent analysis involves evaluating patent filing trends, assessing patent ownership, analyzing the legal status and compliance, and collecting competitive intelligence from patents within the Therapeutic Drug Monitoring Market and its parent industry. Analyzing the ownership of patents, assessing their legal status, and interpreting the patents to gather insights into competitors' technology strategies assist businesses in strategizing and optimizing product positioning and investment decisions.

Trade Analysis

The trade analysis of the Therapeutic Drug Monitoring Market explores the complex interplay of import and export activities, emphasizing the critical role played by key trading nations. This analysis identifies geographical discrepancies in trade flows, offering a deep insight into regional disparities to identify geographic areas suitable for market expansion. A detailed analysis of the regulatory landscape focuses on tariffs, taxes, and customs procedures that significantly determine international trade flows. This analysis is crucial for understanding the overarching legal framework that businesses must navigate.

Regulatory Framework Analysis

The regulatory framework analysis for the Therapeutic Drug Monitoring Market is essential for ensuring legal compliance, managing risks, shaping business strategies, fostering innovation, protecting consumers, accessing markets, maintaining reputation, and managing stakeholder relations. Regulatory frameworks shape business strategies and expansion initiatives, guiding informed decision-making processes. Furthermore, this analysis uncovers avenues for innovation within existing regulations or by advocating for regulatory changes to foster innovation.

FPNV Positioning Matrix

The FPNV positioning matrix is essential in evaluating the market positioning of the vendors in the Therapeutic Drug Monitoring Market. This matrix offers a comprehensive assessment of vendors, examining critical metrics related to business strategy and product satisfaction. This in-depth assessment empowers users to make well-informed decisions aligned with their requirements. Based on the evaluation, the vendors are then categorized into four distinct quadrants representing varying levels of success, namely Forefront (F), Pathfinder (P), Niche (N), or Vital (V).

Market Share Analysis

The market share analysis is a comprehensive tool that provides an insightful and in-depth assessment of the current state of vendors in the Therapeutic Drug Monitoring Market. By meticulously comparing and analyzing vendor contributions, companies are offered a greater understanding of their performance and the challenges they face when competing for market share. These contributions include overall revenue, customer base, and other vital metrics. Additionally, this analysis provides valuable insights into the competitive nature of the sector, including factors such as accumulation, fragmentation dominance, and amalgamation traits observed over the base year period studied. With these illustrative details, vendors can make more informed decisions and devise effective strategies to gain a competitive edge in the market.

Recent Developments

Capitainer announces collaboration with AstraZeneca.

Capitainer, a leading provider of microsampling solutions, has announced a collaboration with AstraZeneca, one of the world's largest pharmaceutical companies. The partnership aims to develop innovative technologies for therapeutic drug monitoring, helping clinicians to optimize patient treatment and improve health outcomes. With Capitainer's cutting-edge sampling technology and AstraZeneca's extensive experience in drug development, the collaboration has the potential to make a significant impact on the future of healthcare. This exciting partnership represents a key step forward in the field of therapeutic drug monitoring, and we look forward to seeing the results of their collaboration.

Novo Holdings invests in proteomics technology company, Evosep.

Novo Holdings, a renowned Danish firm, recently invested in Evosep, a proteomics technology company. Evosep uses groundbreaking approaches to protein analysis to develop innovative solutions to further research on proteomics, which is the study of the proteins that make up biological systems. This partnership will allow Evosep to further develop its cutting-edge technologies, catering to the growing need for advanced proteomics solutions. The collaboration between Novo Holdings and Evosep will not only improve the products and services offered by the latter, but also open new doors for therapeutic drug monitoring, which is an essential component of pharmaceutical research. With the integration of Evosep's proteomics platforms, researchers can now perform highly detailed protein analysis in a quicker, more cost-effective manner. The potential impact of this recent investment can revolutionize the way drugs are developed and monitored, paving the way for an exciting future in the field of proteomics.

AegirBio AB enters into an agreement with Atlas Special Opportunities, LLC regarding convertible bonds of SEK 55 million with attached warrants to intensify investments in i.a. TDM and saliva sampling.

AegirBio AB, a biotech company based in Sweden, has recently entered into a strategic agreement with Atlas Special Opportunities LLC, a reputable investment firm. The agreement pertains to the financing of convertible bonds to further develop AegirBio's technology for therapeutic drug monitoring. This partnership marks a significant milestone for AegirBio, as it signifies the tremendous growth potential of the company's innovative technology in the healthcare industry. With a focus on providing reliable and accurate drug monitoring solutions, AegirBio is poised to further solidify its position in the market and meet the increasing demand for personalized and precise medicine.

Strategy Analysis & Recommendation

The strategic analysis is essential for organizations seeking a solid foothold in the global marketplace. Companies are better positioned to make informed decisions that align with their long-term aspirations by thoroughly evaluating their current standing in the Therapeutic Drug Monitoring Market. This critical assessment involves a thorough analysis of the organization’s resources, capabilities, and overall performance to identify its core strengths and areas for improvement.

Key Company Profiles

The report delves into recent significant developments in the Therapeutic Drug Monitoring Market, highlighting leading vendors and their innovative profiles. These include Abbott Laboratories, Agilent Technologies, Inc., apDia Group, ARK Diagnostics, Inc., ARUP Laboratories, Assay Genie, Bio-Rad Laboratories, Inc., bioMérieux SA, Bühlmann Laboratories AG, Cambridge Life Sciences Limited, Cardinal Health, Inc., Chromsystems Instruments & Chemicals GmbH, Danaher Corporation, DiaSorin SpA, DiaSystem Scandinavia AB, Eagle Biosciences, Inc., Exagen Inc., F. Hoffmann-La Roche AG, Grifols, S.A., H.U. Group Holdings, Inc., Krishgen Biosystems, Merck KGaA, Myriad Genetics, Inc., Neoteryx, LLC by Trajan Group, OneCare Media, LLC, Pfizer Inc., R-Biopharm AG, Randox Laboratories, Ltd., Sekisui Chemical Co Ltd., Siemens Healthineers AG, Svar Life Science AB, Tecan Trading AG, Theradiag SA, Thermo Fisher Scientific, Inc., and Veolia Group.

Market Segmentation & Coverage

This research report categorizes the Therapeutic Drug Monitoring Market to forecast the revenues and analyze trends in each of the following sub-markets:
  • Product
    • Consumables
    • Data Management Services
    • Equipment
      • Chromatography & MS Detectors
      • Clinical Chemistry Analyzers
      • Immunoassay Analyzers
  • Technology
    • Chromatography-MS
      • GC-MS
      • LC-MS
    • Immunoassays
      • Chemiluminescence Immunoassays
      • Colorimetric Immunoassays
      • Fluorescence Immunoassays
      • Radioimmunoassays
    • Proteomic Technologies
  • Drug Class
    • Antiarrhythmic Drugs
    • Antibiotic Drugs
    • Antiepileptic Drugs
    • Bronchodilator Drugs
    • Immunosuppressant Drugs
    • Psychoactive Drugs
  • End-User
    • Hospital Labs
    • Private Labs
  • Region
    • Americas
      • Argentina
      • Brazil
      • Canada
      • Mexico
      • United States
        • California
        • Florida
        • Illinois
        • New York
        • Ohio
        • Pennsylvania
        • Texas
    • Asia-Pacific
      • Australia
      • China
      • India
      • Indonesia
      • Japan
      • Malaysia
      • Philippines
      • Singapore
      • South Korea
      • Taiwan
      • Thailand
      • Vietnam
    • Europe, Middle East & Africa
      • Denmark
      • Egypt
      • Finland
      • France
      • Germany
      • Israel
      • Italy
      • Netherlands
      • Nigeria
      • Norway
      • Poland
      • Qatar
      • Russia
      • Saudi Arabia
      • South Africa
      • Spain
      • Sweden
      • Switzerland
      • Turkey
      • United Arab Emirates
      • United Kingdom

This research report offers invaluable insights into various crucial aspects of the Therapeutic Drug Monitoring Market:

  1. Market Penetration: This section thoroughly overviews the current market landscape, incorporating detailed data from key industry players.
  2. Market Development: The report examines potential growth prospects in emerging markets and assesses expansion opportunities in mature segments.
  3. Market Diversification: This includes detailed information on recent product launches, untapped geographic regions, recent industry developments, and strategic investments.
  4. Competitive Assessment & Intelligence: An in-depth analysis of the competitive landscape is conducted, covering market share, strategic approaches, product range, certifications, regulatory approvals, patent analysis, technology developments, and advancements in the manufacturing capabilities of leading market players.
  5. Product Development & Innovation: This section offers insights into upcoming technologies, research and development efforts, and notable advancements in product innovation.

Additionally, the report addresses key questions to assist stakeholders in making informed decisions:

  1. What is the current market size and projected growth?
  2. Which products, segments, applications, and regions offer promising investment opportunities?
  3. What are the prevailing technology trends and regulatory frameworks?
  4. What is the market share and positioning of the leading vendors?
  5. What revenue sources and strategic opportunities do vendors in the market consider when deciding to enter or exit?

Please note: For this report, the purchase of an Enterprise license allows up to ten worldwide users of an organization access to the report

Please note: This report can be updated on request. Please contact our Customer Experience team using the Ask a Question widget on our website.

With the purchase of this report at the Multi-user License or greater level, you will have access to one hour with an expert analyst who will help you link key findings in the report to the business issues you're addressing. This will need to be used within three months of purchase.

This report also includes a complimentary Excel file with data from the report for purchasers at the Site License or greater level.

Table of Contents

1. Preface
1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Stakeholders
2. Research Methodology
2.1. Define: Research Objective
2.2. Determine: Research Design
2.3. Prepare: Research Instrument
2.4. Collect: Data Source
2.5. Analyze: Data Interpretation
2.6. Formulate: Data Verification
2.7. Publish: Research Report
2.8. Repeat: Report Update
3. Executive Summary4. Market Overview
5. Market Insights
5.1. Market Dynamics
5.1.1. Drivers
5.1.1.1. Increased Demand for Personalized Medicine
5.1.1.2. Rising Adoption of Therapeutic Drug Monitoring Across Various Therapeutic Fields
5.1.1.3. Growing Use and Importance in Patients with Solid Organ Transplantation
5.1.2. Restraints
5.1.2.1. Inadequate Reimbursement Policies
5.1.2.2. Need of High Capital Investments
5.1.3. Opportunities
5.1.3.1. Future Perspectives of Therapeutic Drug Monitoring in Developing Nations
5.1.3.2. Developments in Immunoassay and Other Therapeutic Drug Monitoring Technologies
5.1.4. Challenges
5.1.4.1. Clinical Challenges and Limited Availability of Skilled Laboratory Technicians
5.2. Market Segmentation Analysis
5.2.1. Product: Rising demand for data management services for efficient drug management
5.2.2. End-User: Increasing demand from hospitals where accurate drug management is essential
5.3. Market Trend Analysis
5.4. Cumulative Impact of Russia-Ukraine Conflict
5.5. Cumulative Impact of High Inflation
5.6. Porter’s Five Forces Analysis
5.6.1. Threat of New Entrants
5.6.2. Threat of Substitutes
5.6.3. Bargaining Power of Customers
5.6.4. Bargaining Power of Suppliers
5.6.5. Industry Rivalry
5.7. Value Chain & Critical Path Analysis
5.8. Regulatory Framework Analysis
5.9. Client Customization
6. Therapeutic Drug Monitoring Market, by Product
6.1. Introduction
6.2. Consumables
6.3. Data Management Services
6.4. Equipment
7. Therapeutic Drug Monitoring Market, by Technology
7.1. Introduction
7.2. Chromatography-MS
7.3. Immunoassays
7.4. Proteomic Technologies
8. Therapeutic Drug Monitoring Market, by Drug Class
8.1. Introduction
8.2. Antiarrhythmic Drugs
8.3. Antibiotic Drugs
8.4. Antiepileptic Drugs
8.5. Bronchodilator Drugs
8.6. Immunosuppressant Drugs
8.7. Psychoactive Drugs
9. Therapeutic Drug Monitoring Market, by End-User
9.1. Introduction
9.2. Hospital Labs
9.3. Private Labs
10. Americas Therapeutic Drug Monitoring Market
10.1. Introduction
10.2. Argentina
10.3. Brazil
10.4. Canada
10.5. Mexico
10.6. United States
11. Asia-Pacific Therapeutic Drug Monitoring Market
11.1. Introduction
11.2. Australia
11.3. China
11.4. India
11.5. Indonesia
11.6. Japan
11.7. Malaysia
11.8. Philippines
11.9. Singapore
11.10. South Korea
11.11. Taiwan
11.12. Thailand
11.13. Vietnam
12. Europe, Middle East & Africa Therapeutic Drug Monitoring Market
12.1. Introduction
12.2. Denmark
12.3. Egypt
12.4. Finland
12.5. France
12.6. Germany
12.7. Israel
12.8. Italy
12.9. Netherlands
12.10. Nigeria
12.11. Norway
12.12. Poland
12.13. Qatar
12.14. Russia
12.15. Saudi Arabia
12.16. South Africa
12.17. Spain
12.18. Sweden
12.19. Switzerland
12.20. Turkey
12.21. United Arab Emirates
12.22. United Kingdom
13. Competitive Landscape
13.1. Market Share Analysis, 2023
13.2. FPNV Positioning Matrix, 2023
13.3. Competitive Scenario Analysis
13.3.1. Capitainer announces collaboration with AstraZeneca.
13.3.2. Novo Holdings invests in proteomics technology company, Evosep.
13.3.3. AegirBio AB enters into an agreement with Atlas Special Opportunities, LLC regarding convertible bonds of SEK 55 million with attached warrants to intensify investments in i.a. TDM and saliva sampling.
13.3.4. Clinical LC-MS methods for therapeutic drug monitoring analysis.
13.3.5. Boditech Med has obtained the export license of four TDM products.
13.3.6. Pace Obtains EPA Approval on Method for Detecting Dioxins and Dibenzofurans Through GC-MS/MS Technology.
13.3.7. Bio-Rad Extends Range of Anti-Idiotypic Antibodies for Bioanalysis and Drug Monitoring.
13.3.8. Beckman Coulter and Saladax Biomedical Team Up on Antipsychotic Therapeutic Drug Monitoring.
13.3.9. Ampersand Capital Partners Invests in Syft Technologies, Leading SIFT-MS Solutions Provider.
14. Competitive Portfolio
14.1. Key Company Profiles
14.2. Key Product Portfolio
List of Figures
FIGURE 1. THERAPEUTIC DRUG MONITORING MARKET RESEARCH PROCESS
FIGURE 2. THERAPEUTIC DRUG MONITORING MARKET SIZE, 2023 VS 2030
FIGURE 3. GLOBAL THERAPEUTIC DRUG MONITORING MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 4. GLOBAL THERAPEUTIC DRUG MONITORING MARKET SIZE, BY REGION, 2023 VS 2030 (%)
FIGURE 5. GLOBAL THERAPEUTIC DRUG MONITORING MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 6. THERAPEUTIC DRUG MONITORING MARKET DYNAMICS
FIGURE 7. GLOBAL THERAPEUTIC DRUG MONITORING MARKET SIZE, BY PRODUCT, 2023 VS 2030 (%)
FIGURE 8. GLOBAL THERAPEUTIC DRUG MONITORING MARKET SIZE, BY PRODUCT, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 9. GLOBAL THERAPEUTIC DRUG MONITORING MARKET SIZE, BY TECHNOLOGY, 2023 VS 2030 (%)
FIGURE 10. GLOBAL THERAPEUTIC DRUG MONITORING MARKET SIZE, BY TECHNOLOGY, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 11. GLOBAL THERAPEUTIC DRUG MONITORING MARKET SIZE, BY DRUG CLASS, 2023 VS 2030 (%)
FIGURE 12. GLOBAL THERAPEUTIC DRUG MONITORING MARKET SIZE, BY DRUG CLASS, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 13. GLOBAL THERAPEUTIC DRUG MONITORING MARKET SIZE, BY END-USER, 2023 VS 2030 (%)
FIGURE 14. GLOBAL THERAPEUTIC DRUG MONITORING MARKET SIZE, BY END-USER, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 15. AMERICAS THERAPEUTIC DRUG MONITORING MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
FIGURE 16. AMERICAS THERAPEUTIC DRUG MONITORING MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 17. UNITED STATES THERAPEUTIC DRUG MONITORING MARKET SIZE, BY STATE, 2023 VS 2030 (%)
FIGURE 18. UNITED STATES THERAPEUTIC DRUG MONITORING MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 19. ASIA-PACIFIC THERAPEUTIC DRUG MONITORING MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
FIGURE 20. ASIA-PACIFIC THERAPEUTIC DRUG MONITORING MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 21. EUROPE, MIDDLE EAST & AFRICA THERAPEUTIC DRUG MONITORING MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
FIGURE 22. EUROPE, MIDDLE EAST & AFRICA THERAPEUTIC DRUG MONITORING MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 23. THERAPEUTIC DRUG MONITORING MARKET SHARE, BY KEY PLAYER, 2023
FIGURE 24. THERAPEUTIC DRUG MONITORING MARKET, FPNV POSITIONING MATRIX, 2023
List of Tables
TABLE 1. THERAPEUTIC DRUG MONITORING MARKET SEGMENTATION & COVERAGE
TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
TABLE 3. GLOBAL THERAPEUTIC DRUG MONITORING MARKET SIZE, 2018-2023 (USD MILLION)
TABLE 4. GLOBAL THERAPEUTIC DRUG MONITORING MARKET SIZE, 2024-2030 (USD MILLION)
TABLE 5. GLOBAL THERAPEUTIC DRUG MONITORING MARKET SIZE, BY REGION, 2018-2023 (USD MILLION)
TABLE 6. GLOBAL THERAPEUTIC DRUG MONITORING MARKET SIZE, BY REGION, 2024-2030 (USD MILLION)
TABLE 7. GLOBAL THERAPEUTIC DRUG MONITORING MARKET SIZE, BY PRODUCT, 2018-2023 (USD MILLION)
TABLE 8. GLOBAL THERAPEUTIC DRUG MONITORING MARKET SIZE, BY PRODUCT, 2024-2030 (USD MILLION)
TABLE 9. GLOBAL THERAPEUTIC DRUG MONITORING MARKET SIZE, BY CONSUMABLES, BY REGION, 2018-2023 (USD MILLION)
TABLE 10. GLOBAL THERAPEUTIC DRUG MONITORING MARKET SIZE, BY CONSUMABLES, BY REGION, 2024-2030 (USD MILLION)
TABLE 11. GLOBAL THERAPEUTIC DRUG MONITORING MARKET SIZE, BY DATA MANAGEMENT SERVICES, BY REGION, 2018-2023 (USD MILLION)
TABLE 12. GLOBAL THERAPEUTIC DRUG MONITORING MARKET SIZE, BY DATA MANAGEMENT SERVICES, BY REGION, 2024-2030 (USD MILLION)
TABLE 13. GLOBAL THERAPEUTIC DRUG MONITORING MARKET SIZE, BY EQUIPMENT, BY REGION, 2018-2023 (USD MILLION)
TABLE 14. GLOBAL THERAPEUTIC DRUG MONITORING MARKET SIZE, BY EQUIPMENT, BY REGION, 2024-2030 (USD MILLION)
TABLE 15. GLOBAL THERAPEUTIC DRUG MONITORING MARKET SIZE, BY EQUIPMENT, 2018-2023 (USD MILLION)
TABLE 16. GLOBAL THERAPEUTIC DRUG MONITORING MARKET SIZE, BY EQUIPMENT, 2024-2030 (USD MILLION)
TABLE 17. GLOBAL THERAPEUTIC DRUG MONITORING MARKET SIZE, BY CHROMATOGRAPHY & MS DETECTORS, BY REGION, 2018-2023 (USD MILLION)
TABLE 18. GLOBAL THERAPEUTIC DRUG MONITORING MARKET SIZE, BY CHROMATOGRAPHY & MS DETECTORS, BY REGION, 2024-2030 (USD MILLION)
TABLE 19. GLOBAL THERAPEUTIC DRUG MONITORING MARKET SIZE, BY CLINICAL CHEMISTRY ANALYZERS, BY REGION, 2018-2023 (USD MILLION)
TABLE 20. GLOBAL THERAPEUTIC DRUG MONITORING MARKET SIZE, BY CLINICAL CHEMISTRY ANALYZERS, BY REGION, 2024-2030 (USD MILLION)
TABLE 21. GLOBAL THERAPEUTIC DRUG MONITORING MARKET SIZE, BY IMMUNOASSAY ANALYZERS, BY REGION, 2018-2023 (USD MILLION)
TABLE 22. GLOBAL THERAPEUTIC DRUG MONITORING MARKET SIZE, BY IMMUNOASSAY ANALYZERS, BY REGION, 2024-2030 (USD MILLION)
TABLE 23. GLOBAL THERAPEUTIC DRUG MONITORING MARKET SIZE, BY TECHNOLOGY, 2018-2023 (USD MILLION)
TABLE 24. GLOBAL THERAPEUTIC DRUG MONITORING MARKET SIZE, BY TECHNOLOGY, 2024-2030 (USD MILLION)
TABLE 25. GLOBAL THERAPEUTIC DRUG MONITORING MARKET SIZE, BY CHROMATOGRAPHY-MS, BY REGION, 2018-2023 (USD MILLION)
TABLE 26. GLOBAL THERAPEUTIC DRUG MONITORING MARKET SIZE, BY CHROMATOGRAPHY-MS, BY REGION, 2024-2030 (USD MILLION)
TABLE 27. GLOBAL THERAPEUTIC DRUG MONITORING MARKET SIZE, BY CHROMATOGRAPHY-MS, 2018-2023 (USD MILLION)
TABLE 28. GLOBAL THERAPEUTIC DRUG MONITORING MARKET SIZE, BY CHROMATOGRAPHY-MS, 2024-2030 (USD MILLION)
TABLE 29. GLOBAL THERAPEUTIC DRUG MONITORING MARKET SIZE, BY GC-MS, BY REGION, 2018-2023 (USD MILLION)
TABLE 30. GLOBAL THERAPEUTIC DRUG MONITORING MARKET SIZE, BY GC-MS, BY REGION, 2024-2030 (USD MILLION)
TABLE 31. GLOBAL THERAPEUTIC DRUG MONITORING MARKET SIZE, BY LC-MS, BY REGION, 2018-2023 (USD MILLION)
TABLE 32. GLOBAL THERAPEUTIC DRUG MONITORING MARKET SIZE, BY LC-MS, BY REGION, 2024-2030 (USD MILLION)
TABLE 33. GLOBAL THERAPEUTIC DRUG MONITORING MARKET SIZE, BY IMMUNOASSAYS, BY REGION, 2018-2023 (USD MILLION)
TABLE 34. GLOBAL THERAPEUTIC DRUG MONITORING MARKET SIZE, BY IMMUNOASSAYS, BY REGION, 2024-2030 (USD MILLION)
TABLE 35. GLOBAL THERAPEUTIC DRUG MONITORING MARKET SIZE, BY IMMUNOASSAYS, 2018-2023 (USD MILLION)
TABLE 36. GLOBAL THERAPEUTIC DRUG MONITORING MARKET SIZE, BY IMMUNOASSAYS, 2024-2030 (USD MILLION)
TABLE 37. GLOBAL THERAPEUTIC DRUG MONITORING MARKET SIZE, BY CHEMILUMINESCENCE IMMUNOASSAYS, BY REGION, 2018-2023 (USD MILLION)
TABLE 38. GLOBAL THERAPEUTIC DRUG MONITORING MARKET SIZE, BY CHEMILUMINESCENCE IMMUNOASSAYS, BY REGION, 2024-2030 (USD MILLION)
TABLE 39. GLOBAL THERAPEUTIC DRUG MONITORING MARKET SIZE, BY COLORIMETRIC IMMUNOASSAYS, BY REGION, 2018-2023 (USD MILLION)
TABLE 40. GLOBAL THERAPEUTIC DRUG MONITORING MARKET SIZE, BY COLORIMETRIC IMMUNOASSAYS, BY REGION, 2024-2030 (USD MILLION)
TABLE 41. GLOBAL THERAPEUTIC DRUG MONITORING MARKET SIZE, BY FLUORESCENCE IMMUNOASSAYS, BY REGION, 2018-2023 (USD MILLION)
TABLE 42. GLOBAL THERAPEUTIC DRUG MONITORING MARKET SIZE, BY FLUORESCENCE IMMUNOASSAYS, BY REGION, 2024-2030 (USD MILLION)
TABLE 43. GLOBAL THERAPEUTIC DRUG MONITORING MARKET SIZE, BY RADIOIMMUNOASSAYS, BY REGION, 2018-2023 (USD MILLION)
TABLE 44. GLOBAL THERAPEUTIC DRUG MONITORING MARKET SIZE, BY RADIOIMMUNOASSAYS, BY REGION, 2024-2030 (USD MILLION)
TABLE 45. GLOBAL THERAPEUTIC DRUG MONITORING MARKET SIZE, BY PROTEOMIC TECHNOLOGIES, BY REGION, 2018-2023 (USD MILLION)
TABLE 46. GLOBAL THERAPEUTIC DRUG MONITORING MARKET SIZE, BY PROTEOMIC TECHNOLOGIES, BY REGION, 2024-2030 (USD MILLION)
TABLE 47. GLOBAL THERAPEUTIC DRUG MONITORING MARKET SIZE, BY DRUG CLASS, 2018-2023 (USD MILLION)
TABLE 48. GLOBAL THERAPEUTIC DRUG MONITORING MARKET SIZE, BY DRUG CLASS, 2024-2030 (USD MILLION)
TABLE 49. GLOBAL THERAPEUTIC DRUG MONITORING MARKET SIZE, BY ANTIARRHYTHMIC DRUGS, BY REGION, 2018-2023 (USD MILLION)
TABLE 50. GLOBAL THERAPEUTIC DRUG MONITORING MARKET SIZE, BY ANTIARRHYTHMIC DRUGS, BY REGION, 2024-2030 (USD MILLION)
TABLE 51. GLOBAL THERAPEUTIC DRUG MONITORING MARKET SIZE, BY ANTIBIOTIC DRUGS, BY REGION, 2018-2023 (USD MILLION)
TABLE 52. GLOBAL THERAPEUTIC DRUG MONITORING MARKET SIZE, BY ANTIBIOTIC DRUGS, BY REGION, 2024-2030 (USD MILLION)
TABLE 53. GLOBAL THERAPEUTIC DRUG MONITORING MARKET SIZE, BY ANTIEPILEPTIC DRUGS, BY REGION, 2018-2023 (USD MILLION)
TABLE 54. GLOBAL THERAPEUTIC DRUG MONITORING MARKET SIZE, BY ANTIEPILEPTIC DRUGS, BY REGION, 2024-2030 (USD MILLION)
TABLE 55. GLOBAL THERAPEUTIC DRUG MONITORING MARKET SIZE, BY BRONCHODILATOR DRUGS, BY REGION, 2018-2023 (USD MILLION)
TABLE 56. GLOBAL THERAPEUTIC DRUG MONITORING MARKET SIZE, BY BRONCHODILATOR DRUGS, BY REGION, 2024-2030 (USD MILLION)
TABLE 57. GLOBAL THERAPEUTIC DRUG MONITORING MARKET SIZE, BY IMMUNOSUPPRESSANT DRUGS, BY REGION, 2018-2023 (USD MILLION)
TABLE 58. GLOBAL THERAPEUTIC DRUG MONITORING MARKET SIZE, BY IMMUNOSUPPRESSANT DRUGS, BY REGION, 2024-2030 (USD MILLION)
TABLE 59. GLOBAL THERAPEUTIC DRUG MONITORING MARKET SIZE, BY PSYCHOACTIVE DRUGS, BY REGION, 2018-2023 (USD MILLION)
TABLE 60. GLOBAL THERAPEUTIC DRUG MONITORING MARKET SIZE, BY PSYCHOACTIVE DRUGS, BY REGION, 2024-2030 (USD MILLION)
TABLE 61. GLOBAL THERAPEUTIC DRUG MONITORING MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
TABLE 62. GLOBAL THERAPEUTIC DRUG MONITORING MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
TABLE 63. GLOBAL THERAPEUTIC DRUG MONITORING MARKET SIZE, BY HOSPITAL LABS, BY REGION, 2018-2023 (USD MILLION)
TABLE 64. GLOBAL THERAPEUTIC DRUG MONITORING MARKET SIZE, BY HOSPITAL LABS, BY REGION, 2024-2030 (USD MILLION)
TABLE 65. GLOBAL THERAPEUTIC DRUG MONITORING MARKET SIZE, BY PRIVATE LABS, BY REGION, 2018-2023 (USD MILLION)
TABLE 66. GLOBAL THERAPEUTIC DRUG MONITORING MARKET SIZE, BY PRIVATE LABS, BY REGION, 2024-2030 (USD MILLION)
TABLE 67. AMERICAS THERAPEUTIC DRUG MONITORING MARKET SIZE, BY PRODUCT, 2018-2023 (USD MILLION)
TABLE 68. AMERICAS THERAPEUTIC DRUG MONITORING MARKET SIZE, BY PRODUCT, 2024-2030 (USD MILLION)
TABLE 69. AMERICAS THERAPEUTIC DRUG MONITORING MARKET SIZE, BY EQUIPMENT, 2018-2023 (USD MILLION)
TABLE 70. AMERICAS THERAPEUTIC DRUG MONITORING MARKET SIZE, BY EQUIPMENT, 2024-2030 (USD MILLION)
TABLE 71. AMERICAS THERAPEUTIC DRUG MONITORING MARKET SIZE, BY TECHNOLOGY, 2018-2023 (USD MILLION)
TABLE 72. AMERICAS THERAPEUTIC DRUG MONITORING MARKET SIZE, BY TECHNOLOGY, 2024-2030 (USD MILLION)
TABLE 73. AMERICAS THERAPEUTIC DRUG MONITORING MARKET SIZE, BY CHROMATOGRAPHY-MS, 2018-2023 (USD MILLION)
TABLE 74. AMERICAS THERAPEUTIC DRUG MONITORING MARKET SIZE, BY CHROMATOGRAPHY-MS, 2024-2030 (USD MILLION)
TABLE 75. AMERICAS THERAPEUTIC DRUG MONITORING MARKET SIZE, BY IMMUNOASSAYS, 2018-2023 (USD MILLION)
TABLE 76. AMERICAS THERAPEUTIC DRUG MONITORING MARKET SIZE, BY IMMUNOASSAYS, 2024-2030 (USD MILLION)
TABLE 77. AMERICAS THERAPEUTIC DRUG MONITORING MARKET SIZE, BY DRUG CLASS, 2018-2023 (USD MILLION)
TABLE 78. AMERICAS THERAPEUTIC DRUG MONITORING MARKET SIZE, BY DRUG CLASS, 2024-2030 (USD MILLION)
TABLE 79. AMERICAS THERAPEUTIC DRUG MONITORING MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
TABLE 80. AMERICAS THERAPEUTIC DRUG MONITORING MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
TABLE 81. AMERICAS THERAPEUTIC DRUG MONITORING MARKET SIZE, BY COUNTRY, 2018-2023 (USD MILLION)
TABLE 82. AMERICAS THERAPEUTIC DRUG MONITORING MARKET SIZE, BY COUNTRY, 2024-2030 (USD MILLION)
TABLE 83. ARGENTINA THERAPEUTIC DRUG MONITORING MARKET SIZE, BY PRODUCT, 2018-2023 (USD MILLION)
TABLE 84. ARGENTINA THERAPEUTIC DRUG MONITORING MARKET SIZE, BY PRODUCT, 2024-2030 (USD MILLION)
TABLE 85. ARGENTINA THERAPEUTIC DRUG MONITORING MARKET SIZE, BY EQUIPMENT, 2018-2023 (USD MILLION)
TABLE 86. ARGENTINA THERAPEUTIC DRUG MONITORING MARKET SIZE, BY EQUIPMENT, 2024-2030 (USD MILLION)
TABLE 87. ARGENTINA THERAPEUTIC DRUG MONITORING MARKET SIZE, BY TECHNOLOGY, 2018-2023 (USD MILLION)
TABLE 88. ARGENTINA THERAPEUTIC DRUG MONITORING MARKET SIZE, BY TECHNOLOGY, 2024-2030 (USD MILLION)
TABLE 89. ARGENTINA THERAPEUTIC DRUG MONITORING MARKET SIZE, BY CHROMATOGRAPHY-MS, 2018-2023 (USD MILLION)
TABLE 90. ARGENTINA THERAPEUTIC DRUG MONITORING MARKET SIZE, BY CHROMATOGRAPHY-MS, 2024-2030 (USD MILLION)
TABLE 91. ARGENTINA THERAPEUTIC DRUG MONITORING MARKET SIZE, BY IMMUNOASSAYS, 2018-2023 (USD MILLION)
TABLE 92. ARGENTINA THERAPEUTIC DRUG MONITORING MARKET SIZE, BY IMMUNOASSAYS, 2024-2030 (USD MILLION)
TABLE 93. ARGENTINA THERAPEUTIC DRUG MONITORING MARKET SIZE, BY DRUG CLASS, 2018-2023 (USD MILLION)
TABLE 94. ARGENTINA THERAPEUTIC DRUG MONITORING MARKET SIZE, BY DRUG CLASS, 2024-2030 (USD MILLION)
TABLE 95. ARGENTINA THERAPEUTIC DRUG MONITORING MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
TABLE 96. ARGENTINA THERAPEUTIC DRUG MONITORING MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
TABLE 97. BRAZIL THERAPEUTIC DRUG MONITORING MARKET SIZE, BY PRODUCT, 2018-2023 (USD MILLION)
TABLE 98. BRAZIL THERAPEUTIC DRUG MONITORING MARKET SIZE, BY PRODUCT, 2024-2030 (USD MILLION)
TABLE 99. BRAZIL THERAPEUTIC DRUG MONITORING MARKET SIZE, BY EQUIPMENT, 2018-2023 (USD MILLION)
TABLE 100. BRAZIL THERAPEUTIC DRUG MONITORING MARKET SIZE, BY EQUIPMENT, 2024-2030 (USD MILLION)
TABLE 101. BRAZIL THERAPEUTIC DRUG MONITORING MARKET SIZE, BY TECHNOLOGY, 2018-2023 (USD MILLION)
TABLE 102. BRAZIL THERAPEUTIC DRUG MONITORING MARKET SIZE, BY TECHNOLOGY, 2024-2030 (USD MILLION)
TABLE 103. BRAZIL THERAPEUTIC DRUG MONITORING MARKET SIZE, BY CHROMATOGRAPHY-MS, 2018-2023 (USD MILLION)
TABLE 104. BRAZIL THERAPEUTIC DRUG MONITORING MARKET SIZE, BY CHROMATOGRAPHY-MS, 2024-2030 (USD MILLION)
TABLE 105. BRAZIL THERAPEUTIC DRUG MONITORING MARKET SIZE, BY IMMUNOASSAYS, 2018-2023 (USD MILLION)
TABLE 106. BRAZIL THERAPEUTIC DRUG MONITORING MARKET SIZE, BY IMMUNOASSAYS, 2024-2030 (USD MILLION)
TABLE 107. BRAZIL THERAPEUTIC DRUG MONITORING MARKET SIZE, BY DRUG CLASS, 2018-2023 (USD MILLION)
TABLE 108. BRAZIL THERAPEUTIC DRUG MONITORING MARKET SIZE, BY DRUG CLASS, 2024-2030 (USD MILLION)
TABLE 109. BRAZIL THERAPEUTIC DRUG MONITORING MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
TABLE 110. BRAZIL THERAPEUTIC DRUG MONITORING MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
TABLE 111. CANADA THERAPEUTIC DRUG MONITORING MARKET SIZE, BY PRODUCT, 2018-2023 (USD MILLION)
TABLE 112. CANADA THERAPEUTIC DRUG MONITORING MARKET SIZE, BY PRODUCT, 2024-2030 (USD MILLION)
TABLE 113. CANADA THERAPEUTIC DRUG MONITORING MARKET SIZE, BY EQUIPMENT, 2018-2023 (USD MILLION)
TABLE 114. CANADA THERAPEUTIC DRUG MONITORING MARKET SIZE, BY EQUIPMENT, 2024-2030 (USD MILLION)
TABLE 115. CANADA THERAPEUTIC DRUG MONITORING MARKET SIZE, BY TECHNOLOGY, 2018-2023 (USD MILLION)
TABLE 116. CANADA THERAPEUTIC DRUG MONITORING MARKET SIZE, BY TECHNOLOGY, 2024-2030 (USD MILLION)
TABLE 117. CANADA THERAPEUTIC DRUG MONITORING MARKET SIZE, BY CHROMATOGRAPHY-MS, 2018-2023 (USD MILLION)
TABLE 118. CANADA THERAPEUTIC DRUG MONITORING MARKET SIZE, BY CHROMATOGRAPHY-MS, 2024-2030 (USD MILLION)
TABLE 119. CANADA THERAPEUTIC DRUG MONITORING MARKET SIZE, BY IMMUNOASSAYS, 2018-2023 (USD MILLION)
TABLE 120. CANADA THERAPEUTIC DRUG MONITORING MARKET SIZE, BY IMMUNOASSAYS, 2024-2030 (USD MILLION)
TABLE 121. CANADA THERAPEUTIC DRUG MONITORING MARKET SIZE, BY DRUG CLASS, 2018-2023 (USD MILLION)
TABLE 122. CANADA THERAPEUTIC DRUG MONITORING MARKET SIZE, BY DRUG CLASS, 2024-2030 (USD MILLION)
TABLE 123. CANADA THERAPEUTIC DRUG MONITORING MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
TABLE 124. CANADA THERAPEUTIC DRUG MONITORING MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
TABLE 125. MEXICO THERAPEUTIC DRUG MONITORING MARKET SIZE, BY PRODUCT, 2018-2023 (USD MILLION)
TABLE 126. MEXICO THERAPEUTIC DRUG MONITORING MARKET SIZE, BY PRODUCT, 2024-2030 (USD MILLION)
TABLE 127. MEXICO THERAPEUTIC DRUG MONITORING MARKET SIZE, BY EQUIPMENT, 2018-2023 (USD MILLION)
TABLE 128. MEXICO THERAPEUTIC DRUG MONITORING MARKET SIZE, BY EQUIPMENT, 2024-2030 (USD MILLION)
TABLE 129. MEXICO THERAPEUTIC DRUG MONITORING MARKET SIZE, BY TECHNOLOGY, 2018-2023 (USD MILLION)
TABLE 130. MEXICO THERAPEUTIC DRUG MONITORING MARKET SIZE, BY TECHNOLOGY, 2024-2030 (USD MILLION)
TABLE 131. MEXICO THERAPEUTIC DRUG MONITORING MARKET SIZE, BY CHROMATOGRAPHY-MS, 2018-2023 (USD MILLION)
TABLE 132. MEXICO THERAPEUTIC DRUG MONITORING MARKET SIZE, BY CHROMATOGRAPHY-MS, 2024-2030 (USD MILLION)
TABLE 133. MEXICO THERAPEUTIC DRUG MONITORING MARKET SIZE, BY IMMUNOASSAYS, 2018-2023 (USD MILLION)
TABLE 134. MEXICO THERAPEUTIC DRUG MONITORING MARKET SIZE, BY IMMUNOASSAYS, 2024-2030 (USD MILLION)
TABLE 135. MEXICO THERAPEUTIC DRUG MONITORING MARKET SIZE, BY DRUG CLASS, 2018-2023 (USD MILLION)
TABLE 136. MEXICO THERAPEUTIC DRUG MONITORING MARKET SIZE, BY DRUG CLASS, 2024-2030 (USD MILLION)
TABLE 137. MEXICO THERAPEUTIC DRUG MONITORING MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
TABLE 138. MEXICO THERAPEUTIC DRUG MONITORING MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
TABLE 139. UNITED STATES THERAPEUTIC DRUG MONITORING MARKET SIZE, BY PRODUCT, 2018-2023 (USD MILLION)
TABLE 140. UNITED STATES THERAPEUTIC DRUG MONITORING MARKET SIZE, BY PRODUCT, 2024-2030 (USD MILLION)
TABLE 141. UNITED STATES THERAPEUTIC DRUG MONITORING MARKET SIZE, BY EQUIPMENT, 2018-2023 (USD MILLION)
TABLE 142. UNITED STATES THERAPEUTIC DRUG MONITORING MARKET SIZE, BY EQUIPMENT, 2024-2030 (USD MILLION)
TABLE 143. UNITED STATES THERAPEUTIC DRUG MONITORING MARKET SIZE, BY TECHNOLOGY, 2018-2023 (USD MILLION)
TABLE 144. UNITED STATES THERAPEUTIC DRUG MONITORING MARKET SIZE, BY TECHNOLOGY, 2024-2030 (USD MILLION)
TABLE 145. UNITED STATES THERAPEUTIC DRUG MONITORING MARKET SIZE, BY CHROMATOGRAPHY-MS, 2018-2023 (USD MILLION)
TABLE 146. UNITED STATES THERAPEUTIC DRUG MONITORING MARKET SIZE, BY CHROMATOGRAPHY-MS, 2024-2030 (USD MILLION)
TABLE 147. UNITED STATES THERAPEUTIC DRUG MONITORING MARKET SIZE, BY IMMUNOASSAYS, 2018-2023 (USD MILLION)
TABLE 148. UNITED STATES THERAPEUTIC DRUG MONITORING MARKET SIZE, BY IMMUNOASSAYS, 2024-2030 (USD MILLION)
TABLE 149. UNITED STATES THERAPEUTIC DRUG MONITORING MARKET SIZE, BY DRUG CLASS, 2018-2023 (USD MILLION)
TABLE 150. UNITED STATES THERAPEUTIC DRUG MONITORING MARKET SIZE, BY DRUG CLASS, 2024-2030 (USD MILLION)
TABLE 151. UNITED STATES THERAPEUTIC DRUG MONITORING MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
TABLE 152. UNITED STATES THERAPEUTIC DRUG MONITORING MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
TABLE 153. UNITED STATES THERAPEUTIC DRUG MONITORING MARKET SIZE, BY STATE, 2018-2023 (USD MILLION)
TABLE 154. UNITED STATES THERAPEUTIC DRUG MONITORING MARKET SIZE, BY STATE, 2024-2030 (USD MILLION)
TABLE 155. ASIA-PACIFIC THERAPEUTIC DRUG MONITORING MARKET SIZE, BY PRODUCT, 2018-2023 (USD MILLION)
TABLE 156. ASIA-PACIFIC THERAPEUTIC DRUG MONITORING MARKET SIZE, BY PRODUCT, 2024-2030 (USD MILLION)
TABLE 157. ASIA-PACIFIC THERAPEUTIC DRUG MONITORING MARKET SIZE, BY EQUIPMENT, 2018-2023 (USD MILLION)
TABLE 158. ASIA-PACIFIC THERAPEUTIC DRUG MONITORING MARKET SIZE, BY EQUIPMENT, 2024-2030 (USD MILLION)
TABLE 159. ASIA-PACIFIC THERAPEUTIC DRUG MONITORING MARKET SIZE, BY TECHNOLOGY, 2018-2023 (USD MILLION)
TABLE 160. ASIA-PACIFIC THERAPEUTIC DRUG MONITORING MARKET SIZE, BY TECHNOLOGY, 2024-2030 (USD MILLION)
TABLE 161. ASIA-PACIFIC THERAPEUTIC DRUG MONITORING MARKET SIZE, BY CHROMATOGRAPHY-MS, 2018-2023 (USD MILLION)
TABLE 162. ASIA-PACIFIC THERAPEUTIC DRUG MONITORING MARKET SIZE, BY CHROMATOGRAPHY-MS, 2024-2030 (USD MILLION)
TABLE 163. ASIA-PACIFIC THERAPEUTIC DRUG MONITORING MARKET SIZE, BY IMMUNOASSAYS, 2018-2023 (USD MILLION)
TABLE 164. ASIA-PACIFIC THERAPEUTIC DRUG MONITORING MARKET SIZE, BY IMMUNOASSAYS, 2024-2030 (USD MILLION)
TABLE 165. ASIA-PACIFIC THERAPEUTIC DRUG MONITORING MARKET SIZE, BY DRUG CLASS, 2018-2023 (USD MILLION)
TABLE 166. ASIA-PACIFIC THERAPEUTIC DRUG MONITORING MARKET SIZE, BY DRUG CLASS, 2024-2030 (USD MILLION)
TABLE 167. ASIA-PACIFIC THERAPEUTIC DRUG MONITORING MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
TABLE 168. ASIA-PACIFIC THERAPEUTIC DRUG MONITORING MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
TABLE 169. ASIA-PACIFIC THERAPEUTIC DRUG MONITORING MARKET SIZE, BY COUNTRY, 2018-2023 (USD MILLION)
TABLE 170. ASIA-PACIFIC THERAPEUTIC DRUG MONITORING MARKET SIZE, BY COUNTRY, 2024-2030 (USD MILLION)
TABLE 171. AUSTRALIA THERAPEUTIC DRUG MONITORING MARKET SIZE, BY PRODUCT, 2018-2023 (USD MILLION)
TABLE 172. AUSTRALIA THERAPEUTIC DRUG MONITORING MARKET SIZE, BY PRODUCT, 2024-2030 (USD MILLION)
TABLE 173. AUSTRALIA THERAPEUTIC DRUG MONITORING MARKET SIZE, BY EQUIPMENT, 2018-2023 (USD MILLION)
TABLE 174. AUSTRALIA THERAPEUTIC DRUG MONITORING MARKET SIZE, BY EQUIPMENT, 2024-2030 (USD MILLION)
TABLE 175. AUSTRALIA THERAPEUTIC DRUG MONITORING MARKET SIZE, BY TECHNOLOGY, 2018-2023 (USD MILLION)
TABLE 176. AUSTRALIA THERAPEUTIC DRUG MONITORING MARKET SIZE, BY TECHNOLOGY, 2024-2030 (USD MILLION)
TABLE 177. AUSTRALIA THERAPEUTIC DRUG MONITORING MARKET SIZE, BY CHROMATOGRAPHY-MS, 2018-2023 (USD MILLION)
TABLE 178. AUSTRALIA THERAPEUTIC DRUG MONITORING MARKET SIZE, BY CHROMATOGRAPHY-MS, 2024-2030 (USD MILLION)
TABLE 179. AUSTRALIA THERAPEUTIC DRUG MONITORING MARKET SIZE, BY IMMUNOASSAYS, 2018-2023 (USD MILLION)
TABLE 180. AUSTRALIA THERAPEUTIC DRUG MONITORING MARKET SIZE, BY IMMUNOASSAYS, 2024-2030 (USD MILLION)
TABLE 181. AUSTRALIA THERAPEUTIC DRUG MONITORING MARKET SIZE, BY DRUG CLASS, 2018-2023 (USD MILLION)
TABLE 182. AUSTRALIA THERAPEUTIC DRUG MONITORING MARKET SIZE, BY DRUG CLASS, 2024-2030 (USD MILLION)
TABLE 183. AUSTRALIA THERAPEUTIC DRUG MONITORING MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
TABLE 184. AUSTRALIA THERAPEUTIC DRUG MONITORING MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
TABLE 185. CHINA THERAPEUTIC DRUG MONITORING MARKET SIZE, BY PRODUCT, 2018-2023 (USD MILLION)
TABLE 186. CHINA THERAPEUTIC DRUG MONITORING MARKET SIZE, BY PRODUCT, 2024-2030 (USD MILLION)
TABLE 187. CHINA THERAPEUTIC DRUG MONITORING MARKET SIZE, BY EQUIPMENT, 2018-2023 (USD MILLION)
TABLE 188. CHINA THERAPEUTIC DRUG MONITORING MARKET SIZE, BY EQUIPMENT, 2024-2030 (USD MILLION)
TABLE 189. CHINA THERAPEUTIC DRUG MONITORING MARKET SIZE, BY TECHNOLOGY, 2018-2023 (USD MILLION)
TABLE 190. CHINA THERAPEUTIC DRUG MONITORING MARKET SIZE, BY TECHNOLOGY, 2024-2030 (USD MILLION)
TABLE 191. CHINA THERAPEUTIC DRUG MONITORING MARKET SIZE, BY CHROMATOGRAPHY-MS, 2018-2023 (USD MILLION)
TABLE 192. CHINA THERAPEUTIC DRUG MONITORING MARKET SIZE, BY CHROMATOGRAPHY-MS, 2024-2030 (USD MILLION)
TABLE 193. CHINA THERAPEUTIC DRUG MONITORING MARKET SIZE, BY IMMUNOASSAYS, 2018-2023 (USD MILLION)
TABLE 194. CHINA THERAPEUTIC DRUG MONITORING MARKET SIZE, BY IMMUNOASSAYS, 2024-2030 (USD MILLION)
TABLE 195. CHINA THERAPEUTIC DRUG MONITORING MARKET SIZE, BY DRUG CLASS, 2018-2023 (USD MILLION)
TABLE 196. CHINA THERAPEUTIC DRUG MONITORING MARKET SIZE, BY DRUG CLASS, 2024-2030 (USD MILLION)
TABLE 197. CHINA THERAPEUTIC DRUG MONITORING MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
TABLE 198. CHINA THERAPEUTIC DRUG MONITORING MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
TABLE 199. INDIA THERAPEUTIC DRUG MONITORING MARKET SIZE, BY PRODUCT, 2018-2023 (USD MILLION)
TABLE 200. INDIA THERAPEUTIC DRUG MONITORING MARKET SIZE, BY PRODUCT, 2024-2030 (USD MILLION)
TABLE 201. INDIA THERAPEUTIC DRUG MONITORING MARKET SIZE, BY EQUIPMENT, 2018-2023 (USD MILLION)
TABLE 202. INDIA THERAPEUTIC DRUG MONITORING MARKET SIZE, BY EQUIPMENT, 2024-2030 (USD MILLION)
TABLE 203. INDIA THERAPEUTIC DRUG MONITORING MARKET SIZE, BY TECHNOLOGY, 2018-2023 (USD MILLION)
TABLE 204. INDIA THERAPEUTIC DRUG MONITORING MARKET SIZE, BY TECHNOLOGY, 2024-2030 (USD MILLION)
TABLE 205. INDIA THERAPEUTIC DRUG MONITORING MARKET SIZE, BY CHROMATOGRAPHY-MS, 2018-2023 (USD MILLION)
TABLE 206. INDIA THERAPEUTIC DRUG MONITORING MARKET SIZE, BY CHROMATOGRAPHY-MS, 2024-2030 (USD MILLION)
TABLE 207. INDIA THERAPEUTIC DRUG MONITORING MARKET SIZE, BY IMMUNOASSAYS, 2018-2023 (USD MILLION)
TABLE 208. INDIA THERAPEUTIC DRUG MONITORING MARKET SIZE, BY IMMUNOASSAYS, 2024-2030 (USD MILLION)
TABLE 209. INDIA THERAPEUTIC DRUG MONITORING MARKET SIZE, BY DRUG CLASS, 2018-2023 (USD MILLION)
TABLE 210. INDIA THERAPEUTIC DRUG MONITORING MARKET SIZE, BY DRUG CLASS, 2024-2030 (USD MILLION)
TABLE 211. INDIA THERAPEUTIC DRUG MONITORING MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
TABLE 212. INDIA THERAPEUTIC DRUG MONITORING MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
TABLE 213. INDONESIA THERAPEUTIC DRUG MONITORING MARKET SIZE, BY PRODUCT, 2018-2023 (USD MILLION)
TABLE 214. INDONESIA THERAPEUTIC DRUG MONITORING MARKET SIZE, BY PRODUCT, 2024-2030 (USD MILLION)
TABLE 215. INDONESIA THERAPEUTIC DRUG MONITORING MARKET SIZE, BY EQUIPMENT, 2018-2023 (USD MILLION)
TABLE 216. INDONESIA THERAPEUTIC DRUG MONITORING MARKET SIZE, BY EQUIPMENT, 2024-2030 (USD MILLION)
TABLE 217. INDONESIA THERAPEUTIC DRUG MONITORING MARKET SIZE, BY TECHNOLOGY, 2018-2023 (USD MILLION)
TABLE 218. INDONESIA THERAPEUTIC DRUG MONITORING MARKET SIZE, BY TECHNOLOGY, 2024-2030 (USD MILLION)
TABLE 219. INDONESIA THERAPEUTIC DRUG MONITORING MARKET SIZE, BY CHROMATOGRAPHY-MS, 2018-2023 (USD MILLION)
TABLE 220. INDONESIA THERAPEUTIC DRUG MONITORING MARKET SIZE, BY CHROMATOGRAPHY-MS, 2024-2030 (USD MILLION)
TABLE 221. INDONESIA THERAPEUTIC DRUG MONITORING MARKET SIZE, BY IMMUNOASSAYS, 2018-2023 (USD MILLION)
TABLE 222. INDONESIA THERAPEUTIC DRUG MONITORING MARKET SIZE, BY IMMUNOASSAYS, 2024-2030 (USD MILLION)
TABLE 223. INDONESIA THERAPEUTIC DRUG MONITORING MARKET SIZE, BY DRUG CLASS, 2018-2023 (USD MILLION)
TABLE 224. INDONESIA THERAPEUTIC DRUG MONITORING MARKET SIZE, BY DRUG CLASS, 2024-2030 (USD MILLION)
TABLE 225. INDONESIA THERAPEUTIC DRUG MONITORING MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
TABLE 226. INDONESIA THERAPEUTIC DRUG MONITORING MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
TABLE 227. JAPAN THERAPEUTIC DRUG MONITORING MARKET SIZE, BY PRODUCT, 2018-2023 (USD MILLION)
TABLE 228. JAPAN THERAPEUTIC DRUG MONITORING MARKET SIZE, BY PRODUCT, 2024-2030 (USD MILLION)
TABLE 229. JAPAN THERAPEUTIC DRUG MONITORING MARKET SIZE, BY EQUIPMENT, 2018-2023 (USD MILLION)
TABLE 230. JAPAN THERAPEUTIC DRUG MONITORING MARKET SIZE, BY EQUIPMENT, 2024-2030 (USD MILLION)
TABLE 231. JAPAN THERAPEUTIC DRUG MONITORING MARKET SIZE, BY TECHNOLOGY, 2018-2023 (USD MILLION)
TABLE 232. JAPAN THERAPEUTIC DRUG MONITORING MARKET SIZE, BY TECHNOLOGY, 2024-2030 (USD MILLION)
TABLE 233. JAPAN THERAPEUTIC DRUG MONITORING MARKET SIZE, BY CHROMATOGRAPHY-MS, 2018-2023 (USD MILLION)
TABLE 234. JAPAN THERAPEUTIC DRUG MONITORING MARKET SIZE, BY CHROMATOGRAPHY-MS, 2024-2030 (USD MILLION)
TABLE 235. JAPAN THERAPEUTIC DRUG MONITORING MARKET SIZE, BY IMMUNOASSAYS, 2018-2023 (USD MILLION)
TABLE 236. JAPAN THERAPEUTIC DRUG MONITORING MARKET SIZE, BY IMMUNOASSAYS, 2024-2030 (USD MILLION)
TABLE 237. JAPAN THERAPEUTIC DRUG MONITORING MARKET SIZE, BY DRUG CLASS, 2018-2023 (USD MILLION)
TABLE 238. JAPAN THERAPEUTIC DRUG MONITORING MARKET SIZE, BY DRUG CLASS, 2024-2030 (USD MILLION)
TABLE 239. JAPAN THERAPEUTIC DRUG MONITORING MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
TABLE 240. JAPAN THERAPEUTIC DRUG MONITORING MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
TABLE 241. MALAYSIA THERAPEUTIC DRUG MONITORING MARKET SIZE, BY PRODUCT, 2018-2023 (USD MILLION)
TABLE 242. MALAYSIA THERAPEUTIC DRUG MONITORING MARKET SIZE, BY PRODUCT, 2024-2030 (USD MILLION)
TABLE 243. MALAYSIA THERAPEUTIC DRUG MONITORING MARKET SIZE, BY EQUIPMENT, 2018-2023 (USD MILLION)
TABLE 244. MALAYSIA THERAPEUTIC DRUG MONITORING MARKET SIZE, BY EQUIPMENT, 2024-2030 (USD MILLION)
TABLE 245. MALAYSIA THERAPEUTIC DRUG MONITORING MARKET SIZE, BY TECHNOLOGY, 2018-2023 (USD MILLION)
TABLE 246. MALAYSIA THERAPEUTIC DRUG MONITORING MARKET SIZE, BY TECHNOLOGY, 2024-2030 (USD MILLION)
TABLE 247. MALAYSIA THERAPEUTIC DRUG MONITORING MARKET SIZE, BY CHROMATOGRAPHY-MS, 2018-2023 (USD MILLION)
TABLE 248. MALAYSIA THERAPEUTIC DRUG MONITORING MARKET SIZE, BY CHROMATOGRAPHY-MS, 2024-2030 (USD MILLION)
TABLE 249. MALAYSIA THERAPEUTIC DRUG MONITORING MARKET SIZE, BY IMMUNOASSAYS, 2018-2023 (USD MILLION)
TABLE 250. MALAYSIA THERAPEUTIC DRUG MONITORING MARKET SIZE, BY IMMUNOASSAYS, 2024-2030 (USD MILLION)
TABLE 251. MALAYSIA THERAPEUTIC DRUG MONITORING MARKET SIZE, BY DRUG CLASS, 2018-2023 (USD MILLION)
TABLE 252. MALAYSIA THERAPEUTIC DRUG MONITORING MARKET SIZE, BY DRUG CLASS, 2024-2030 (USD MILLION)
TABLE 253. MALAYSIA THERAPEUTIC DRUG MONITORING MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
TABLE 254. MALAYSIA THERAPEUTIC DRUG MONITORING MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
TABLE 255. PHILIPPINES THERAPEUTIC DRUG MONITORING MARKET SIZE, BY PRODUCT, 2018-2023 (USD MILLION)
TABLE 256. PHILIPPINES THERAPEUTIC DRUG MONITORING MARKET SIZE, BY PRODUCT, 2024-2030 (USD MILLION)
TABLE 257. PHILIPPINES THERAPEUTIC DRUG MONITORING MARKET SIZE, BY EQUIPMENT, 2018-2023 (USD MILLION)
TABLE 258. PHILIPPINES THERAPEUTIC DRUG MONITORING MARKET SIZE, BY EQUIPMENT, 2024-2030 (USD MILLION)
TABLE 259. PHILIPPINES THERAPEUTIC DRUG MONITORING MARKET SIZE, BY TECHNOLOGY, 2018-2023 (USD MILLION)
TABLE 260. PHILIPPINES THERAPEUTIC DRUG MONITORING MARKET SIZE, BY TECHNOLOGY, 2024-2030 (USD MILLION)
TABLE 261. PHILIPPINES THERAPEUTIC DRUG MONITORING MARKET SIZE, BY CHROMATOGRAPHY-MS, 2018-2023 (USD MILLION)
TABLE 262. PHILIPPINES THERAPEUTIC DRUG MONITORING MARKET SIZE, BY CHROMATOGRAPHY-MS, 2024-2030 (USD MILLION)
TABLE 263. PHILIPPINES THERAPEUTIC DRUG MONITORING MARKET SIZE, BY IMMUNOASSAYS, 2018-2023 (USD MILLION)
TABLE 264. PHILIPPINES THERAPEUTIC DRUG MONITORING MARKET SIZE, BY IMMUNOASSAYS, 2024-2030 (USD MILLION)
TABLE 265. PHILIPPINES THERAPEUTIC DRUG MONITORING MARKET SIZE, BY DRUG CLASS, 2018-2023 (USD MILLION)
TABLE 266. PHILIPPINES THERAPEUTIC DRUG MONITORING MARKET SIZE, BY DRUG CLASS, 2024-2030 (USD MILLION)
TABLE 267. PHILIPPINES THERAPEUTIC DRUG MONITORING MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
TABLE 268. PHILIPPINES THERAPEUTIC DRUG MONITORING MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
TABLE 269. SINGAPORE THERAPEUTIC DRUG MONITORING MARKET SIZE, BY PRODUCT, 2018-2023 (USD MILLION)
TABLE 270. SINGAPORE THERAPEUTIC DRUG MONITORING MARKET SIZE, BY PRODUCT, 2024-2030 (USD MILLION)
TABLE 271. SINGAPORE THERAPEUTIC DRUG MONITORING MARKET SIZE, BY EQUIPMENT, 2018-2023 (USD MILLION)
TABLE 272. SINGAPORE THERAPEUTIC DRUG MONITORING MARKET SIZE, BY EQUIPMENT, 2024-2030 (USD MILLION)
TABLE 273. SINGAPORE THERAPEUTIC DRUG MONITORING MARKET SIZE, BY TECHNOLOGY, 2018-2023 (USD MILLION)
TABLE 274. SINGAPORE THERAPEUTIC DRUG MONITORING MARKET SIZE, BY TECHNOLOGY, 2024-2030 (USD MILLION)
TABLE 275. SINGAPORE THERAPEUTIC DRUG MONITORING MARKET SIZE, BY CHROMATOGRAPHY-MS, 2018-2023 (USD MILLION)
TABLE 276. SINGAPORE THERAPEUTIC DRUG MONITORING MARKET SIZE, BY CHROMATOGRAPHY-MS, 2024-2030 (USD MILLION)
TABLE 277. SINGAPORE THERAPEUTIC DRUG MONITORING MARKET SIZE, BY IMMUNOASSAYS, 2018-2023 (USD MILLION)
TABLE 278. SINGAPORE THERAPEUTIC DRUG MONITORING MARKET SIZE, BY IMMUNOASSAYS, 2024-2030 (USD MILLION)
TABLE 279. SINGAPORE THERAPEUTIC DRUG MONITORING MARKET SIZE, BY DRUG CLASS, 2018-2023 (USD MILLION)
TABLE 280. SINGAPORE THERAPEUTIC DRUG MONITORING MARKET SIZE, BY DRUG CLASS, 2024-2030 (USD MILLION)
TABLE 281. SINGAPORE THERAPEUTIC DRUG MONITORING MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
TABLE 282. SINGAPORE THERAPEUTIC DRUG MONITORING MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
TABLE 283. SOUTH KOREA THERAPEUTIC DRUG MONITORING MARKET SIZE, BY PRODUCT, 2018-2023 (USD MILLION)
TABLE 284. SOUTH KOREA THERAPEUTIC DRUG MONITORING MARKET SIZE, BY PRODUCT, 2024-2030 (USD MILLION)
TABLE 285. SOUTH KOREA THERAPEUTIC DRUG MONITORING MARKET SIZE, BY EQUIPMENT, 2018-2023 (USD MILLION)
TABLE 286. SOUTH KOREA THERAPEUTIC DRUG MONITORING MARKET SIZE, BY EQUIPMENT, 2024-2030 (USD MILLION)
TABLE 287. SOUTH KOREA THERAPEUTIC DRUG MONITORING MARKET SIZE, BY TECHNOLOGY, 2018-2023 (USD MILLION)
TABLE 288. SOUTH KOREA THERAPEUTIC DRUG MONITORING MARKET SIZE, BY TECHNOLOGY, 2024-2030 (USD MILLION)
TABLE 289. SOUTH KOREA THERAPEUTIC DRUG MONITORING MARKET SIZE, BY CHROMATOGRAPHY-MS, 2018-2023 (USD MILLION)
TABLE 290. SOUTH KOREA THERAPEUTIC DRUG MONITORING MARKET SIZE, BY CHROMATOGRAPHY-MS, 2024-2030 (USD MILLION)
TABLE 291. SOUTH KOREA THERAPEUTIC DRUG MONITORING MARKET SIZE, BY IMMUNOASSAYS, 2018-2023 (USD MILLION)
TABLE 292. SOUTH KOREA THERAPEUTIC DRUG MONITORING MARKET SIZE, BY IMMUNOASSAYS, 2024-2030 (USD MILLION)
TABLE 293. SOUTH KOREA THERAPEUTIC DRUG MONITORING MARKET SIZE, BY DRUG CLASS, 2018-2023 (USD MILLION)
TABLE 294. SOUTH KOREA THERAPEUTIC DRUG MONITORING MARKET SIZE, BY DRUG CLASS, 2024-2030 (USD MILLION)
TABLE 295. SOUTH KOREA THERAPEUTIC DRUG MONITORING MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
TABLE 296. SOUTH KOREA THERAPEUTIC DRUG MONITORING MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
TABLE 297. TAIWAN THERAPEUTIC DRUG MONITORING MARKET SIZE, BY PRODUCT, 2018-2023 (USD MILLION)
TABLE 298. TAIWAN THERAPEUTIC DRUG MONITORING MARKET SIZE, BY PRODUCT, 2024-2030 (USD MILLION)
TABLE 299. TAIWAN THERAPEUTIC DRUG MONITORING MARKET SIZE, BY EQUIPMENT, 2018-2023 (USD MILLION)
TABLE 300. TAIWAN THERAPEUTIC DRUG MONITORING MARKET SIZE, BY EQUIPMENT, 2024-2030 (USD MILLION)
TABLE 301. TAIWAN THERAPEUTIC DRUG MONITORING MARKET SIZE, BY TECHNOLOGY, 2018-2023 (USD MILLION)
TABLE 302. TAIWAN THERAPEUTIC DRUG MONITORING MARKET SIZE, BY TECHNOLOGY, 2024-2030 (USD MILLION)
TABLE 303. TAIWAN THERAPEUTIC DRUG MONITORING MARKET SIZE, BY CHROMATOGRAPHY-MS, 2018-2023 (USD MILLION)
TABLE 304. TAIWAN THERAPEUTIC DRUG MONITORING MARKET SIZE, BY CHROMATOGRAPHY-MS, 2024-2030 (USD MILLION)
TABLE 305. TAIWAN THERAPEUTIC DRUG MONITORING MARKET SIZE, BY IMMUNOASSAYS, 2018-2023 (USD MILLION)
TABLE 306. TAIWAN THERAPEUTIC DRUG MONITORING MARKET SIZE, BY IMMUNOASSAYS, 2024-2030 (USD MILLION)
TABLE 307. TAIWAN THERAPEUTIC DRUG MONITORING MARKET SIZE, BY DRUG CLASS, 2018-2023 (USD MILLION)
TABLE 308. TAIWAN THERAPEUTIC DRUG MONITORING MARKET SIZE, BY DRUG CLASS, 2024-2030 (USD MILLION)
TABLE 309. TAIWAN THERAPEUTIC DRUG MONITORING MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
TABLE 310. TAIWAN THERAPEUTIC DRUG MONITORING MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
TABLE 311. THAILAND THERAPEUTIC DRUG MONITORING MARKET SIZE, BY PRODUCT, 2018-2023 (USD MILLION)
TABLE 312. THAILAND THERAPEUTIC DRUG MONITORING MARKET SIZE, BY PRODUCT, 2024-2030 (USD MILLION)
TABLE 313. THAILAND THERAPEUTIC DRUG MONITORING MARKET SIZE, BY EQUIPMENT, 2018-2023 (USD MILLION)
TABLE 314. THAILAND THERAPEUTIC DRUG MONITORING MARKET SIZE, BY EQUIPMENT, 2024-2030 (USD MILLION)
TABLE 315. THAILAND THERAPEUTIC DRUG MONITORING MARKET SIZE, BY TECHNOLOGY, 2018-2023 (USD MILLION)
TABLE 316. THAILAND THERAPEUTIC DRUG MONITORING MARKET SIZE, BY TECHNOLOGY, 2024-2030 (USD MILLION)
TABLE 317. THAILAND THERAPEUTIC DRUG MONITORING MARKET SIZE, BY CHROMATOGRAPHY-MS, 2018-2023 (USD MILLION)
TABLE 318. THAILAND THERAPEUTIC DRUG MONITORING MARKET SIZE, BY CHROMATOGRAPHY-MS, 2024-2030 (USD MILLION)
TABLE 319. THAILAND THERAPEUTIC DRUG MONITORING MARKET SIZE, BY IMMUNOASSAYS, 2018-2023 (USD MILLION)
TABLE 320. THAILAND THERAPEUTIC DRUG MONITORING MARKET SIZE, BY IMMUNOASSAYS, 2024-2030 (USD MILLION)
TABLE 321. THAILAND THERAPEUTIC DRUG MONITORING MARKET SIZE, BY DRUG CLASS, 2018-2

Companies Mentioned

  • Abbott Laboratories
  • Agilent Technologies, Inc.
  • apDia Group
  • ARK Diagnostics, Inc.
  • ARUP Laboratories
  • Assay Genie
  • Bio-Rad Laboratories, Inc.
  • bioMérieux SA
  • Bühlmann Laboratories AG
  • Cambridge Life Sciences Limited
  • Cardinal Health, Inc.
  • Chromsystems Instruments & Chemicals GmbH
  • Danaher Corporation
  • DiaSorin SpA
  • DiaSystem Scandinavia AB
  • Eagle Biosciences, Inc.
  • Exagen Inc.
  • F. Hoffmann-La Roche AG
  • Grifols, S.A.
  • H.U. Group Holdings, Inc.
  • Krishgen Biosystems
  • Merck KGaA
  • Myriad Genetics, Inc.
  • Neoteryx, LLC by Trajan Group
  • OneCare Media, LLC
  • Pfizer Inc.
  • R-Biopharm AG
  • Randox Laboratories, Ltd.
  • Sekisui Chemical Co Ltd.
  • Siemens Healthineers AG
  • Svar Life Science AB
  • Tecan Trading AG
  • Theradiag SA
  • Thermo Fisher Scientific, Inc.
  • Veolia Group

Methodology

Loading
LOADING...

Table Information